Lexaria releases additional results from Phase 1b study GLP-1-H24-4 [Yahoo! Finance]
Lexaria Bioscience Corp. (LEXX)
Company Research
Source: Yahoo! Finance
chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH study arms relative to the Rybelsus control study arm. At week 16, rough parity was reached between the DHT arms and the Rybelsus control as there were no statistically significant treatment differences observed in terms of the numerical least squares means changes from baseline in the secondary efficacy parameters of mean fasting glucose, cholesterol, and low density lipoprotein cholesterol specifically. While both DHT-semaglutide and Rybelsus reduced body weight during the Study, it was noteworthy that upon a separate body composition analysis performed in the Study using the dual-energy, X-ray absorptiometry / Bioelectrical Impedance Analysis methodology, at week 12, the DHT-semaglutide arm showed a modest numerical LSM reduction in fat mass of -1.08 kg and in total mass of -1.40 kg, accompanied by minimal reduction in lean mass of -0.41 kg. In contrast, the Rybelsus control arm achieved greater L
Show less
Read more
Impact Snapshot
Event Time:
LEXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEXX alerts
High impacting Lexaria Bioscience Corp. news events
Weekly update
A roundup of the hottest topics
LEXX
News
- Lexaria Bioscience (NASDAQ:LEXX) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Lexaria Bioscience (NASDAQ:LEXX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Lexaria Bioscience (NASDAQ:LEXX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=LEXX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Lexaria Bioscience (NASDAQ:LEXX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Lexaria Bioscience Corp. (NASDAQ:LEXX): Are Analysts Optimistic? [Yahoo! Finance]Yahoo! Finance
LEXX
Analyst Actions
- 12/26/25 - HC Wainwright
LEXX
Sec Filings
- 12/29/25 - Form S-3
- 12/19/25 - Form D
- 12/16/25 - Form 8-K
- LEXX's page on the SEC website